The CooperCOO +4.04%85 ROA % is -2.50% as of Apr. 2026. GuruFocus rates COO with a GF Score™ of 85/100 and a GF Value™ of $100.85 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 857 Medical Devices & Instruments companies, The Cooper ranks better than 55.78% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. The Cooper's annualizedNet Income for the quarter that ended in Apr. 2026 was $-312 Mil.
The Cooper's average Total Assets over the quarter that ended in Apr. 2026 was $12,453 Mil. Therefore, The Cooper's annualized ROA % for the quarter that ended in Apr. 2026 was -2.50%.
The historical rank and industry rank for The Cooper's ROA % or its related term are showing as below:
COO'
s ROA % Range Over the Past 10 Years
Min: 1.9 Med: 3.66 Max: 36.03
Current: 1.9
During the past 13 years, The Cooper's highest ROA % was 36.03%. The lowest was 1.90%. And the median was 3.66%.
COO's ROA % is ranked better than 55.78% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs COO: 1.90
The Cooper (NAS:COO) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Apr. 2026) net income data. The Revenue data used here is four times the quarterly (Apr. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
The Cooper ROA % Related Terms
The Cooper ROA % Historical Data
* Premium members only.
The historical data trend for The Cooper's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, The Cooper's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's ROA % distribution charts can be found below:
* The bar in red indicates where The Cooper's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Apr. 2026) net income data.
ROA % is displayed in the 30-year financial page.
The Cooper (COO) has a ROA % of -2.50% as of Apr. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on The Cooper and its competitors. Over the past decade, The Cooper's ROA % has ranged from 1.90 to 36.03. According to the industry distribution chart, The Cooper ranks #379 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 44.2%.
Is The Cooper's ROA % too high?
The Cooper's current ROA % is -2.50%. Over the past 10 years, this metric has ranged from a low of 1.90 to a high of 36.03. Based on the distribution chart, The Cooper ranks #379 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's ROA % compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #379 out of 857 companies for ROA %. This puts The Cooper in the upper half of its industry. The industry median ROA % is 0.59. Historically, The Cooper's own ROA % has ranged from 1.90 to 36.03 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current ROA % is -2.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $100.85, compared to a current price of $68.83 — trading 31.8% below its estimated fair value. The current ROA % is -2.50%. The Cooper's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For The Cooper (COO), the current ROA % is -2.50% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $68.83 is trading 31.8% below its estimated GF Value™ of $100.85.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
ROA %: -2.50%
GF Value™: $100.85 vs. price of $68.83 (31.8% below fair value)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
85GF Score
Get the complete analysis for COO
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
